Low levels of gene delivery in vivo using replication-defective retroviral vectors have severely limited their application for clinical protocols. To overcome this problem, we describe here a semi-replication-competent retrovirus (s-RCR) in which the gag-pol and envelope (VSV-G, vesicular stomatitis virus G protein) genes were split into two vectors. This system offers potential advantages over both replicationdefective vectors, in terms of efficiency of in vivo spread through a tumor, and all-in-one replication-competent vectors in terms of the payload of therapeutic genes that can be carried. We achieved a viral titer of s-RCR viruses approximately 70-fold higher than VSV-G pseudotyped, replicationdefective vectors. In addition, s-RCR vectors induced tumor killing by the cytotoxicity of VSV-G during viral spread. Inclusion of the herpes simplex virus thymidine kinase (HSVtk30) gene into vectors significantly improved tumor killing activity followed by ganciclovir (GCV) treatment in vitro under conditions of low-level viral replication. However, at high levels of viral spread, VSV-G-mediated cytotoxicity predominated. Xenografts of human fibrosarcoma HT1080 cells, preinfected by semi-replicative green fluorescent protein vectors (semi-GFP), were completely non-tumorigenic in nude mice. Implantation of cells preinfected by semireplicative TK30 vectors (semi-TK30) mixed with parental HT1080 cells at a ratio of 1:1 efficiently prevented tumor growth in mice treated by GCV. Direct intratumoral injection of HT1080 tumors growing in nude mice, or B16 murine melanoma in immunocompetent mice, with semi-TK30 viruses significantly prolonged survival. Injection of autologous cells (B16) producing semi-TK30 vector into B16 tumors prolonged survival only in mice treated with GCV but not with phosphate-buffered saline (PBS). In contrast, when xenogeneic cells (293T) producing semi-TK30 vectors were injected into B16 tumors, an optimal survival advantage was obtained in mice treated with PBS rather than GCV. These data indicate that complex interactions exist between direct cytotoxicity of VSV-G and HSVtk expression when placed in the context of additional immune parameters, which combine to determine the efficacy of the therapy. Taken together, our data suggest that s-RCR vectors have some potential advantages for development to deliver genes into tumors for cancer treatment but that a combination of factors will impact on the decision as to whether the s-RCR strategy is worth developing to full clinical trials.
Introduction
Recombinant Moloney murine leukemia virus (MoMuLV)-based retroviral vectors have been extensively developed for use in gene therapy. The specific targeting of dividing cells with murine leukemia virus (MLV) vectors provides an excellent opportunity for cancer gene therapy compared to other types of vector. However, low levels of gene delivery in vivo using replication-defective retroviral vectors have severely limited their application for clinical protocols. In order to overcome this problem, methods to generate viral stocks with higher titers, or viral producer cells with higher viral yields, have been developed. In this respect, use of VSV-G (vesicular stomatitis virus G protein) to pseudotype MuLV vectors allows viral supernatants to be concentrated by ultracentrifugation to obtain high titers of viral stocks. 1 It has also been reported that levels of transduction of human cancer cells with VSV-G pseudotyped retroviral vectors are higher than with traditional amphotropic, or other pseudotyped, retroviral vectors. 2, 3 The herpes simplex virus thymidine kinase (HSVtk) gene has been widely used as a therapeutic gene for cancer therapy, as its expression in eukaryotic cells induces a toxic effect in the presence of the prodrug ganciclovir (GCV). An important attribute of this strategy is the bystander effect, which allows HSVtk + -expressing cells to kill neighboring HSVtk À cells. 4 Several groups have shown that complete tumor regressions can be obtained with only a small proportion of tumor cells expressing HSVtk mediated by retroviral vectors. [5] [6] [7] [8] However, results of clinical trials using retroviral-based HSVtk/GCV suicide gene therapy showed very few antitumor responses, although there were no major toxicities. 9, 10 These trials also showed extremely low levels of gene transduction in the tumor following engraftment of retroviral producer cells. 9 Low levels of GCV sensitivity 11, 12 and poor bystander effects in human cancer cells 13 could also be responsible for the lack of efficacy in this approach. In the light of these clinical findings, we have been interested in developing replication-competent retroviral vectors to preserve the theoretical advantages of using retroviral-mediated gene transfer to tumors while at the same time overcoming the low levels of gene transfer mediated by replicationdefective retroviruses.
Use of a replication-competent retroviral vector encoding a therapeutic gene for treatment of experimental brain tumors has been recently reported. 14, 15 However, as epitomized by these studies, the insert capacity for therapeutic transgenes is severely restricted (to about 1.3 kb) in fully replication-competent retroviruses. For this reason, we investigated whether it would be possible to develop a novel, semi-replicating retrovirus design, which would allow larger inserts to be used. We describe here a strategy that uses a pair of replication-defective vectors -one expressing the gag-pol genes and one expressing an env gene -which, in a dually infected cell, will complement each other to generate infectious viral particles. By using two separate vectors, there is potentially a much higher payload capacity available (total of B7.3 kb) to include multiple additional therapeutic genes than is the case with the conventional, all-in-one replication-competent retroviral vector. In addition, we have been interested in the combined cytotoxic and immunogenic potential of the VSV-G transgene. Therefore, we incorporated the VSV-G envelope as the env gene into one of our pair of replication-defective vectors in order to exploit the VSV-G protein both as a pseudotyping viral envelope 1 and as a therapeutic cytotoxic/immunostimulatory protein. 1, [16] [17] [18] In this scenario, the env gene also serves as a therapeutic gene leaving plenty of additional space for further therapeutic genes in either, or both, of the individual vectors. In vitro, the semi-replicative vectors induced both viral spread and tumor cell killing owing to VSV-G toxicity. In vitro, this cytotoxicity was significantly improved by incorporating a potent HSV-tk mutant (HSVtk30) suicide gene into gag-pol vector partner, followed by GCV treatment. Complete tumor eradication was observed in mice implanted by HT1080 cells in which half of the cells had been preinfected with the pair of vectors expressing VSV-G and TK30 (semi-TK30) when GCV was administered; in contrast, all mice developed progressively growing tumors following implantation of a 1:1 mix of HT180 cells+HT1080 preinfected with the pair of vectors expressing VSV-G and green fluorescent protein (semi-GFP). Direct intratumoral injection of the semi-TK30 viruses significantly prolonged survival in both HT1080 tumors (in nude mice) and B16 tumors (in immunocompetent mice). To explore additional therapeutic avenues using these semi-replication-competent vectors, we also delivered the vector pairs via direct intratumoral injection of autologous or xenogeneic cells. Although the therapeutic effects of the semi-replication-competent vector strategy were only modest in our models, our results suggest that VSV-G can play a significant therapeutic role in tumor regressions. Interestingly, inclusion of the HSVtk gene and GCV treatment can be neutral or can either inhibit or augment these effects depending upon additional factors contributing to the therapeutic strategy that is used.
Results

Construction of s-RCR vectors and s-RCR virus production
We designed two complimentary replication-defective vectors, which could result in viral propagation from cells infected by both vectors. All our constructs are based on MFGb2, an Mo-MuLV vector that leads to highlevel gene expression in transduced cells (Figure 1 ). 19 In order to generate vector pairs that would allow high insert capacities for additional therapeutic transgenes, we partitioned the gag-pol and env genes into two separate vectors. We also deleted the final 100 bp of the envelope sequence that is contained in MFGb2 parental vector to create the MFGgagpol vector (Figure 1 ). In the vectors MFGgagpoliresGFP or MFGgagpoliresTK30, the viral genome is transcribed under the control of the MoMuLV long terminal repeat (MLV-LTR) (Figure 1 ), and translation of either the GFP or TK30 genes is initiated from the an internal ribosome entry site (IRES) upstream of GFP or TK30 for cap-independent translation. 20 This allows titration of viral stocks by fluorescence-activated cell sorting (FACS) analysis of GFP-positive cells, or by selection of cellular thymidine kinase-negative cells (143BTK À cells) in HAT (hypoxanthine, aminopterine, thymidine) medium (see Materials and methods). In the partner vector, we inserted the cDNA for the VSV-G gene (1.67 kb), which is itself smaller than either the ecotropic or amphotropic envelope genes (B2 kb), thereby conferring even more insert capacity for future constructs. MFG-VSVG encodes the VSV-G envelope gene tran- (1) MFGgagpol contains the murine leukemia virus long terminal repeat (MLV 5 0 LTR), the adjacent sequence between the 5 0 LTR and gagpol, the entire gagpol coding sequence and the sequence from the 3 0 non-coding region of the genome to the end of 3 0 LTR. (2, 3) An iresGFP, or iresTK30, cassette was introduced downstream of the gag-pol sequence of MFGgagpol. (4) The 1.67 kb cDNA of vesicular stomatitis virus G protein (VSV-G) was inserted into the MFGb2 backbone. Co-transfection of MFG-VSVG with any of vectors 1-3 generates s-RCR viruses. SD and SA, splice donor and acceptor sequences. The LTR probe used in Southern blotting was as indicated using NheI to digest genomic DNA of infected cells. Nh, P, N and B represent restriction enzyme sites for NheI, PstI, NcoI or BamH1, respectively. s-RCR for cancer treatment J Qiao et al scribed from MLV-LTR ( Figure 1 ). Both vectors are replication defective, but co-transfection of MFG-VSVG with either MFGgagpoliresGFP or MFGgagpoliresTK30 into 293T cells generated semi-replicating vector stocks, referred to as semi-GFP or semi-TK30, respectively. Use of an internal promoter (cytomegalovirus, CMV) driving VSV-G led to a lower viral titer of semi-replicationcompetent retrovirus (s-RCR) compared to those using MFG-VSVG (data not shown).
Characterization of s-RCR viruses in vitro
As VSV-G is toxic in most mammalian cells, 1, 21 we hypothesized that if the s-RCR viruses spread in culture, the level of VSV-G expression will increase with time, leading to increasing killing of the 293T cells. Cotransfection of MFGgagpol with MFG-VSVG into 293T cells did indeed lead to a progressive toxicity of these cultures. In contrast, when MFGgagpol was co-transfected with the non-retroviral pCMV-VSV-G plasmid, which will generate only a VSV-G pseudotyped, replication-defective MFGgagpol virus that would not be expected to spread in vitro, limited toxicity and cell death were only observed at early time points posttransfection ( Figure 2a ). Progressively developing toxicity associated with spreading VSV-G expression was also observed on cells directly infected by s-RCR or semi-GFP viruses harvested from these initially transfected 293T cells (Figure 2b ). However, there was no toxicity observed following infection by either replication-defective viruses (RDR-GFP or RDR-VSVG) or by wild-type GFP (w.t.GFP) viruses (data not shown).
To confirm ongoing spread of s-RCR from the initially transfected cultures, we tested s-RCR viral replication on three different cell lines derived from human, mouse and hamster, respectively ( Figure 3 ). Semi-GFP s-RCR stocks harvested from transfected 293T cultures infected both HT1080 (multiplicity of infection (MOI) of 30) (Figure 3a ) and BHK-21 (MOI of 5) cells (Figure 3b ). (As VSV-G induces fusion of BHK-21 cells spontaneously in culture, but requires an acid shock for HT1080 and B16 cells, we used a lower MOI for BHK-21 than HT1080 in order to prevent toxicity before viral replication was complete.) At 48 or 72 h after this infection, before high levels of cell killing had occurred, supernatants were harvested and used for a second round of infection of new target cells. Flow cytometry for GFP expression on these new target cells (HT1080 and B16) demonstrated that both HT1080 and BHK-21 cells can propagate and release the s-RCR vectors following a first round of infection from transfected cell supernatants (Figure 3a and b) . In contrast, when a replication-defective virus stock (RDR-GFP) was harvested from transfected 293T cells, no infectious virus was detected either on the second round of infection (HT1080 or BHK-21) or in any subsequent rounds of infection (data not shown). Supernatants from the second round of infection of HT1080 or B16 cells also initiated productive infection of new target cells, indicating that s-RCR viruses continued to replicate through several passages in vitro, although there is also a clear fall off of efficiency of spread upon multiple passages of the virus (Figure 3a) . The influence of the MOI of initial infection on the efficiency of viral replication using our VSV-G pseudotyped system, through both cell culture and tumors in vivo, is discussed in detail in the Discussion section.
We also assessed whether viral propagation, as measured by GFP expression, could also be followed by observing spreading cell fusion as a surrogate of VSV-G expression/toxicity. BHK-21 cells spontaneously fuse with expression of VSV-G without the need for the acid shock, which is required to induce fusion of HT1080 or B16 cells. We observed progressive syncytial formation, accompanied by cell death, at 7 days post-infection at an MOI of 5 transduction units (TU)/cell (Figure 3b and data not shown). Supernatants from the second round of infection with semi-GFP viruses also induced syncytial formation in BHK-21 cells (Figure 3c ), further confirming that s-RCR viruses replicated and spread through cultures as assessed by cell fusion induced by VSV-G expression in BHK-21 cells. Syncytial formation in BHK-21 cells infected by both first and second rounds of infection with semi-GFP viruses mirrored closely the results with GFP in that increases in the levels of GFP transduction were always proportionally matched by changes in the levels of syncytial number and size.
The titers of semi-GFP virus reached 7.3 Â 10 6 TU/ml by FACS analysis of GFP expression compared to that of RDR-GFP at 1.05 Â 10 5 TU/ml. We also investigated the kinetics of viral production over a 12-day period from 293T cells using defined input stocks. Table 1 shows that semi-GFP viruses progressively replicated through the 293T culture with time, whereas the RDR-GFP virus did not. Similar studies following the transfer of syncytial induction onto indicator BHK-21 cells 22 confirmed these results ( Table 2) .
Taken together, these results show that co-transfection of MFGgagpol or MFGgagpoliresGFP with MFG-VSVG generated s-RCR viruses, which can spread through both transfected and subsequently infected cultures and that this spread is accompanied by cytotoxicity associated with VSV-G expression.
Tumor killing can be enhanced in vitro by expression of HSVtk30/GCV We confirmed that the MFGgagpoliresTK30 and MFG-VSVG vector pairs, generating the s-RCR semi-TK30, showed similar properties of in vitro viral spread and replication as for the semi-GFP s-RCR (Figure 2b and data not shown). We therefore evaluated whether target cell killing by the semi-TK30 viral stocks could be enhanced by the addition of GCV treatment. Whereas infection of HT1080 cells at a high MOI (approximately 30 TU/cell) of either semi-GFP or semi-TK30 stocks induced significant toxicity during viral spread due to high levels of VSV-G expression (Figure 4a ), cytotoxicity due to VSV-G alone (semi-GFP or semi-TK30 in the absence of GCV) was much reduced at low MOI; in contrast, the addition of GCV treatment to infection with semi-TK30 viral stocks induced significant levels of cytotoxicity compared with semi-GFP viruses ( Figure  4b , Po0.0001). Cell cytotoxicity induced by infection with semi-GFP was abrogated by 3 0 -azido-3 0 -deoxythymidine (AZT) treatment, reflecting an inhibition of viral replication and, therefore, the associated VSV-G expression. However, AZT had no effect on cytotoxicity associated with infection by semi-TK30 virus in the presence of GCV, indicating that, at these low MOIs, infection of cells with only a single vector may be predominating and that, under such circumstances, viral 
In vivo anti-tumor effects and viral replication
To test whether s-RCR vectors replicated, and had antitumor effects in vivo, we implanted preinfected HT1080 cells, or a mixture of preinfected cells with parental cells at a ratio of 1:1. HT1080 xenografts preinfected by semi-GFP virus were completely nontumorigenic in athymic nu/nu mice ( Figure 5a ). We could not detect integrated vector in a range of normal organs tested by PCR, indicating no wide spread dissemination of the vectors from injected tumor cells that we know are producing high titers of virus. Therefore, we believe that this assay is a good representation of whether viral producer cells can generate s-RCR, which circulates and productively infects other tissues ( Figure 5b ). Mice implanted with parental cells mixed with preinfected cells showed significantly prolonged survival but the mixtures in which parental cells were mixed with cells preinfected by semi-TK30 viruses were eradicated in all mice treated by GCV ( Figure 5a ). Thus, the combination of suicide gene therapy (HSVtk30/GCV) greatly increased the antitumor effects in vivo compared to the s-RCR viruses alone (semi-GFP). To confirm replication of semi-GFP viruses, tumors were removed from mice that were killed and flow cytometry for GFP expression was performed immediately after the tumor was dissociated. In all tumors from cells preinfected by replication-defective vectors, or from preinfected cells mixed with parental cells, the percentage of GFP-positive cells was low (3-6%) and, significantly, no virus could be detected in the culture supernatants from the explanted cells in vitro (Table 3 ). In contrast, tumors that developed from cells preinfected by semi-GFP mixed with parental cells maintained the percentage of GFP-positive cells at levels of 42.15-53% except for one tumor (33.48%) ( Table 3) . Three out of five of these tumors produced detectable viruses during culture in vitro. These data confirm that the s-RCR vectors replicated in the tumors in vivo, although the lack of expansion in the proportion of cells expressing GFP (beyond the 50% input level) suggests that spread through the tumor is limited.
In vivo treatment of established subcutaneous tumors by direct intratumoral injection
To test the efficacy of the s-RCR vectors in a more realistic therapeutic context, semi-TK30 viruses were directly injected into HT1080 tumors once a day for 3 days. Control tumors injected with phosphate-buffered saline (PBS) grew rapidly and all mice died before 21 days after tumor seeding. The mice injected by semi-TK30 viruses survived significantly longer compared to the control mice (P ¼ 0.005) ( Figure 6 ). However, there was no significant difference between the survival of the semi-TK30/GCV and that of the semi-TK30/PBS group ( Figure 6 ). We never obtained significant antitumor effects by injection of replication-defective vectors, or by only one injection of semi-TK30 viruses (data not shown).
Effective gene therapy of established tumors in immunocompetent mice by direct intratumoral injection
We further investigated whether semi-TK30 virus would have antitumor effects in an immunocompetent mice model. Intratumoral injection of semi-TK30 viruses into B16 murine melanomas in C57BL/6 mice generated significant survival benefits compared to control injected tumors ( Figure 7a ). Prolongation of survival was more significant in the mice treated with GCV (P ¼ 0.003) compared to mice treated with PBS (P ¼ 0.03) (Figure 7a ) but there was no statistical difference between these two treatment groups.
To increase the efficiency of delivery of our s-RCR system to tumors in vivo, we used intratumoral injection of cell lines already producing the s-RCR. Survival of mice treated by intratumoral injections of B16 semi-TK30 viral producer cells, followed by GCV treatment, was significantly prolonged (P ¼ 0.03) compared to control injected groups. However, these effects were not seen following PBS treatment compared to control treated mice (Figure 7b ). In contrast, when 293T semi-TK30 viral producer cells were injected into tumors, optimal survival advantage, with one complete tumor regression, was obtained in mice treated with PBS rather than GCV (Figure 7c ). However, in the absence of a full immune system, the same survival advantage was observed with a Two days post-infection, BHK21 cells were stained by crystal violet after glutaraldehyde fixation. Cell fusions were quantified under a microscope by counting syncytia containing more than four nuclei in 4-10 independent fields. b The same viral supernatants were used as in Table 1 . c Diluting factor of viral supernatant. time, and at specific time points, in the immunocompetent mice (data not shown).
We therefore hypothesized that VSV-G as a viral immunogen, combined with the immune adjuvant effect of xenogeneic producer cells (293T), may play a potent role in the induction of antitumor immune response in immunocompetent mice (Figure 7c ).
Viral genomic stability
To study viral genome stability in the infected cells, we first infected HT1080 cells by semi-GFP viral stock at an MOI of 10 or 20. Seventeen days after infection, DNA was extracted and used for Southern blot analysis. We also extracted DNA from transduced HT1080 cells at 80 days after a second round of viral infection (Figure 3a) to detect viral genomes by Southern blot analysis. The MFGgagpoliresGFP vector was detected using a GFPspecific probe, and both vector partners, as well as any derivative species formed by recombination, were detected by an LTR-specific probe. DNA from tumor explants from the in vivo experiment of Table 3 was also extracted to study the viral genome stability. Both the MFGgagpoliresGFP and MFG-VSVG vectors maintained the full length of viral genome, and no deletion or recombination mutants could be detected in this assay ( Figure 8 ). The vector containing VSV-G was less prominent presumably due to the cytotoxicity of VSV-G either in vitro or in vivo (Figure 8b ).
Discussion
In the light of recent findings about the dangers of insertional mutagenesis by retroviral vectors, we have been interested in studying the ability of individual, replication-defective MLV vectors to be mobilized within tumors by endogenous viral elements. In particular, the MFGgagpoliresGFP vector is a useful tool to study the efficiency with which endogenous envelope expression within tumor cells might generate either replicationcompetent or at least pseudotyped replication-defective virus. Similarly, an MFG-ENV vector can be used to study the presence of tumor-associated, endogenous retroviral functions that might be associated with vector mobilization in vivo. At the same time, we reasoned that we might combine these two vectors in a protocol that would preserve the advantages of the use of C-type retroviral vectors for cancer gene therapy, while increasing the efficiency of viral spread through a tumor relative to that produced by a replication-defective vector. To this end, we developed a semi-replication-competent system in which two separate vectors, each replication defective, could generate fully infectious virus from a cell that was infected by both vectors simultaneously. One theoretical advantage of such a system is that each vector could include space for an additional therapeutic gene, or genes, of a total of B7.3 kb, which would considerably improve upon that achievable with previously described all-in-one replication-competent retroviral vectors. 15, 23 A second advantage of this approach is that spread through a tumor should be significantly more efficient than would be the case with a single hit replication-defective vector. Moreover, we reasoned that we could add yet more potency by including the VSV-G gene in one of the vectors. In this scenario, VSV-G would serve dual roles 
05). No tumors developed in mice injected with cells preinfected by semi-GFP (E).
Tumors were established by a mixture of preinfected HT1080 cells by semi-TK30 viruses with parental cells; the ganciclovir (GCV) or phosphate-buffered saline (PBS) was given for 14 days starting 7 days (when tumors were palpable) after the tumor cell inoculation ( Â ) (n ¼ 5/6 mice per group). (b) Biodistribution of viruses in normal organs after injection of viral producer cells into nude mice. Total DNA was prepared from liver, lung, spleen, heart, brain, kidney, ovaries and bone marrow removed from mice 10 months after injection of HT1080 viral producer cells (semi-GFP group in (a)). PCR analysis was performed for integrated proviral DNA of semi-GFP viruses. Total DNA isolated from tumor cells (derived from the Mix.semi-GFP group in (a)) was used as a positive control. Days Post Tumor Cells Injection Figure 6 Intratumoral injection of semi-TK30 into established human HT1080 fibrosarcoma (subcutaneously (s.c.)) in nude mice. Three injections of phosphate-buffered saline (PBS) (n ¼ 8) or semi-TK30 (n ¼ 5) viruses were given intratumorally, followed by treatment with PBS or ganciclovir (GCV) (25 mg/kg, twice daily, intraperitoneally (i.p.)) for 2 weeks starting 2 days after the last virus injection. Significant survival was obtained by viral treatment in combination with either PBS or GCV compared to control mice (P ¼ 0.005).
s-RCR for cancer treatment J Qiao et al both as a pseudotyping viral envelope to mediate efficient viral entry and spread and as a potent cytotoxic and immunostimulatory gene.
1-3,16-18
The data presented here show that it is possible to construct a pair of complimenting replication-defective vectors that can, when infecting the same cell, generate fully infectious viral progeny. In vitro, the infection of cells with s-RCR viruses sets up a spreading infection of the semi-replication-competent pair of vectors, which can lead to transduction of close to 100% of the cells. Moreover, the pseudotyping VSV-G envelope also confers significant direct cytotoxicity in vitro. Significantly, this cytotoxicity does not prevent the establishment of a full spreading viral infection, a concern that has been Table 3 ; tumor explants from mouse #4 (lane 6) and mouse #5 (lane 7) from the Mix.semi-GFP group of Table 3 ; lanes 8 (1 pg), 9 (10 pg), 10 (100 pg) MFG-VSVG plasmid.
(b) Hybridization with LTR probe. P1: 100 pg MFGgagpoliresGFP plasmid; P2: 100 pg MFG-VSVG plasmid; lanes 1-7 as for (a). The data presented in each Southern blot were from the same experiment.
s-RCR for cancer treatment J Qiao et al raised about the arming of oncolytic viruses with additional therapeutic genes. Using the MFGgagpoliresTK30/MFG-VSVG vector pair in which we express two potentially therapeutic genes, we observed two distinct phenotypes for the efficacy of the s-RCR strategy in vitro. Following infection of cells at a high MOI, the semi-TK30 virus stocks induced significant toxicity during viral spread owing to high levels of VSV-G expression, a phenomenon also seen with the semi-GFP vector pair. This cytotoxicity was abrogated by AZT treatment, reflecting an inhibition of viral replication and, therefore, the associated VSV-G expression. In contrast, cytotoxicity due to VSV-G alone (semi-GFP or semi-TK30 in the absence of GCV) was much reduced at low MOI and the addition of GCV treatment to infection with semi-TK30 viral stocks became the predominant inducer of cell killing under these conditions. Consistent with this, AZT had no effect on cytotoxicity associated with infection by semi-TK30 virus in the presence of GCV. We interpret these results to show that a high MOI with both vector pairs is initially required to initiate a spreading s-RCR infection of a culture, presumably because a high MOI of each virus is necessary to ensure that enough target cells will be infected by both vectors to generate further rounds of progeny virus. When this occurs, viral spread distributes the VSV-G gene to many cells and most cells carry both the MFGgagpoliresTK30 vector and the MFG-VSVG vector. Therefore, VSV-G toxicity is the predominant method of cell killing and the slower developing HSVtk/ GCV toxicity superimposed upon this has small or no additive effects (hence the lack of benefit of GCV to killing these cultures and the dependence upon AZT for limiting toxicity associated with viral replication). On the other hand, where only a low MOI is initially used, the magnitude of the viral spread is very low and cells become infected by one, or other, of the vector pairs but rarely by both. In these circumstances, viral spread is not possible and HSVtk expression becomes a major factor in cytotoxicity because most of the cells are not infected with both VSV-G and HSVtk transgenes. In this case, GCV treatment confers significant therapy by eradicating those cells just infected by the MFGgagpoliresTK30 vector and AZT treatment is not a factor as cytotoxicity is not associated with viral replication.
These in vitro findings were largely recapitulated by our in vivo data. Thus, preinfection of HT1080 tumor cells with s-RCR (GFP or TK30) led to a complete loss of tumorigenicity in nude mice irrespective of HSVtk expression. However, when preinfected cells were mixed with parental cells at a 1:1 mix although survival was significantly improved if the cells had been preinfected with the s-RCR, GCV treatment was required to eradicate tumors completely. These results are reminiscent of our in vitro studies where the equivalent of a low MOI of input tumor cells (an MOI of o1) shifted the dependence of cytotoxicity from viral replication-associated VSV-G expression to HSVtk-mediated cytotoxicity. We also observed that tumor explants from tumors established from a 1:1 mix of parental cells and parental cells infected with the semi-GFP vector maintained GFP levels at about 40-50% of the cells. These data clearly suggest that the s-RCR vectors replicated in the tumors in vivo, although the lack of expansion in the proportion of cells expressing GFP (beyond the 50% input level) suggests that spread through the tumor is not extremely efficient. This may be due in part to loss of cells expressing either the VSV-G and/or GFP transgene products, both of which have been shown to be targets of immune responses, 24, 25 which are still operative even in nude mice (such as NK-cell-mediated effects). Therefore, NK-mediated destruction of infected tumor cells may both contribute to the therapeutic clearances that we see and prevent higher levels of colonization of the tumor by cells expressing GFP.
Similarly, when cell-free stocks of semi-TK30 were injected directly into tumors, significant therapy was seen although there was no added effect by administering GCV in either immunodeficient or immunocompetent mice. We believe that the direct intratumoral injection establishes a high local concentration of virus, where, at the site of injection, most cells receive both vectors and so set up a spreading infection with the s-RCR. Under these circumstances, cytotoxicity becomes predominantly dependent upon viral replication and VSV-G expression (as also seen for the in vitro situation). The slower developing cytotoxicity of HSVtk/GCV is therefore not significantly beneficial because most cells infected by MFGgagpoliresTK30 are also infected by MFG-VSVG and will die because of the VSV-G-mediated effects (both direct and, possibly, immune mediated). In the case of the direct injections of semi-TK30 into B16 tumors in immunocompetent C57Bl/6 mice, the GCV-treated group was more effective than the PBStreated group relative to the control group perhaps because of the additional immunopotentiating effects of GCV-mediated killing of B16 cell expressing HSVtk in vivo, as we have previously reported. 26 However, there was still no statistically significant difference between the therapy produced in semi-TK30 injected tumors given GCV or PBS.
In order to increase the efficiency of delivery of our s-RCR system to tumors in vivo, we used intratumoral injection of cell lines already producing the s-RCR. These experiments revealed a complex interaction between the effects of VSV-G-and HSVtk-mediated direct cytotoxicity and components of the immune-mediated clearance of tumors. So, when B16 (autologous) cells producing semi-TK30 viruses were injected directly into B16 tumors in fully immunocompetent mice, significant therapy was produced only in the presence of co-administered GCV. We have previously shown that HSVtk-mediated killing of B16 tumor cells in immunocompetent mice is itself potently immunostimulatory. 26 We have also shown previously that VSV-G is a potent immune adjuvant in the generation of antitumor effects. 16, 18 Therefore, by killing a relatively large number of injected B16VPC (VPC: viral producer cells) with GCV, we would expect to stimulate antitumor immune responses, which would contribute to therapy. Thus, GCV is needed to generate those responses (by killing the VPC) and is therefore beneficial to the therapy. When we injected xenogeneic 293T cells producing semi-tk30 viruses, however, the converse was true and better therapy resulted when GCV was not administered. We showed previously that an allogeneic vaccine of VSV-G-mediated cell fusion is more potent than autologous vaccine in the B16 model. 16 We believe that GCV may worsen the effects with 293TVPC because these producer cells induce an antitumor, immune-mediated effect as a result of injection s-RCR for cancer treatment J Qiao et al of xenogeneic cells, as well as VSV-G expression, into an immune-competent host. However, by administering GCV, these xenogenic cells are killed more rapidly in vivo and their immunopotentiating, anti-tumor effects are lost to the therapy. The antitumor effects are not solely mediated by these xenogeneic effects however, as intratumoral injection of non-virus producing 293T cells was not effective (data not shown). Further experiments are ongoing to dissect the relative contributions of viral replication, VSV-G and HSVtk expression and immune parameters to the efficacy of these therapies. Recombination between two vectors in a semi-replication-competent system using an ecotropic envelope, and deletion of a fully replicating MLV vector with an insert more than 1.3 kb size, has been reported previously. 23, 27 In contrast, the viral genome of our s-RCR vectors was very stable. Mutants owing to vector deletion, or recombination, were not detected in our assays by Southern blot, whereas the entire proviral DNA of both vectors was detected even at 80 days post-infection of HT1080 tumor cells. In the light of a report that leukemia was induced in recent clinical trials with retrovirally transduced hematopoietic cells for treatment of immunodeficiency syndrome, [28] [29] [30] the inclusion of a suicide gene into one of our vectors would be an added safety feature to delete any cells that may become transformed by retroviral insertion over time. The other vector contains VSV-G gene that will also act to prevent long-term transformation due to its toxicity. In fact, we never detected vector sequences extratumorally when we implanted the viral producer cells in nude mice ( Figure  5b ). Nor were we able to detect the TK or the VSV-G gene in tumors by PCR analysis after GCV treatment of B16 tumors in immuno-competent mice treated by semi-TK30 viruses or viral producer cells (Figure 7 and data not shown).
The semi-replication-competent retroviral vector system described here offers potential advantages over both replication-defective vectors, in terms of efficiency of in vivo spread through a tumor, and all-in-one replication-competent vectors in terms of the payload of therapeutic genes that it can carry. However, our data have raised several important issues that must be addressed before this system is taken further. Although it is likely that relatively low MOIs of vector delivery will be achievable by direct intratumoral injections over the whole tumor mass, we reasoned that the chances of hitting the same tumor cell locally (at the site of the injection) with both vectors might be relatively high. We had hoped therefore that a spreading infection may be initiated through the tumor and these predictions are largely supported by our in vivo data. We saw spread of the s-RCR vector through established human xenograft tumors and levels of tumor transduction well in excess of that produced by a single injection of a replicationdefective vector. However, we could never reach anywhere near 100% of the tumor cells transduced in vivo. In a study reported by Trajcevski et al., 31 using a semireplication-competent MuLV vector pseudotyped with 4070 envelope, an increased percentage of GFP-positive cells was observed ranging from 2% to a plateau of 30% by 3 days post-implantation of a population of mixed tumor cells and VPCs. In another report, using the MuLV gag-pol, 4070 envelope and a GFP cDNA in a single viral genome, up to 85% of tumor cells were transduced in vivo.
14 Other groups have also been able to achieve high transduction levels approaching 100% of tumor cells using fully replicating MuLV vectors. 15, 32 We believe that the difference in the levels of viral spread between these two systems (semi-replicating vs fully replicating) is because semi-replicative viruses are diluted as tumors grow, and because viral receptor interference blocked viral spread in the case of using 4070 envelope. 31, 33 In our case, viral producer cells are most likely deleted owing to both direct toxicity and immunostimulatory effects of VSV-G by using VSV-G envelope, although VSV-G has the advantage of overcoming viral receptor interference. 33 Together, these effects will decrease the overall viral production spread. Therefore, although our results do not compare favorably with the levels of in vivo tumor cell transduction that can be achieved by other replication-competent oncolytic viruses, be they retroviral 15 or otherwise, [34] [35] [36] [37] nonetheless, we did still see appreciable levels of tumor cell transduction and this was accompanied by significant therapeutic effects (which may additionally be dependent upon several immune parameters). The real advantages of the s-RCR approach over, for example, all-in-one replication-competent retroviruses or oncolytic viruses to which additional genes of choice cannot be added have yet to be tested by engineering additional cytotoxic or immunopotentiating genes. The combination of all of these factors will have to be carefully weighed and will, therefore, impact on the decision as to whether the s-RCR strategy is worth developing to full clinical trials.
Materials and methods
Cell lines
293T cells (human embryonic kidney), HT1080 cells (human fibrosarcoma, ATCC CCL-121), 143B cells (human osteosarcoma, ATCC CRL-8303), B16 cells (mouse melanoma) and BHK-21 cells (baby hamster kidney fibroblast) were cultured with Dulbecco's modified Eagle's minimal essential medium (Life Technologies, Rockville, MD, USA) supplemented with 10% fetal calf serum (Life Technologies). All cell lines were monitored routinely and found to be free of Mycoplasma infection.
s-RCR vector construction and virus production
The retroviral vectors constructed in this study were based on a modified version of MFG vector referred to as MFGb2. 19 The entire gag-pol encoding sequence was derived from the plasmid of CeB 38 (kindly provided by Dr FL Cosset). Several subcloning steps were performed to make MFGgagpol with a linker sequence positioned between the 3 0 end of the gag-pol gene and the 3 0 noncoding region (at nt 7775) of the Mo-MLV genome sequence. The MFGgagpol construct has an entire 5 0 LTR, the adjacent sequence between the 5 0 LTR and gagpol, the gagpol gene, the 3 0 non-coding region and the full 3 0 LTR from wild-type Mo-MuLV (MFGgagpol still carries the B2 mutant 19 ). The GFP (780 bp) (Clontech, Palo Alto, CA, USA) or TK30 (1.1 kb) 39, 40 genes were ligated downstream of the IRES (derived from encephalomyocarditis virus), which has been described previously by us to mediate high translation efficiency in bicistronic retroviral vector. 20 IresGFP or iresTK30 was inserted into the NotI site (blunted) of the linker sequence of MFGgagpol s-RCR for cancer treatment J Qiao et al to generate MFGgagpoliresGFP or MFGgagpoliresTK30. MFG-VSVG was constructed by cloning the 1.67-kb VSV-G gene into MFGb2, digested with NcoI/BamH1. The VSV-G cDNA was released by EcoRI from pCMV-VSV-G (a kind gift of Dr Y Takeuchi, London, UK). To generate retroviruses, transient transfections were performed on 293T cells in a 10-cm plate by the calcium phosphate precipitation. For s-RCR virus production, MFGgagpol or MFGgagpoliresGFP (TK30) plasmid was co-transfected with the same amount of MFG-VSVG plasmid (15 mg/ each). For production of replication-defective vectors (RDR), MFGgagpoliresGFP(TK30) with pCMV-VSV-G or cNDA3gagpol with MFG-VSVG was co-transfected to generate RDR-GFP (TK30) or RDR-VSVG, respectively. w.t.GFP viruses were generated by co-transfection of MFG-GFP 20 and an infectious proviral DNA plasmid, PBSK-A (kindly provided by Dr FL Cosset). All viral supernatants harvested from 293T cells were passed through 0.45 mm filters and stored at À801C or concentrated by ultracentrifugation. 1 
Viral titer determination
To determine viral titer, 2 Â 10 5 HT1080 cells or 143B cells per well were seeded in a six-well plate 1 day before infection. A 1 ml portion of a series of dilutions of viral supernatant in culture media was added to the cells in the presence of 8 mg/ml of polybrene (Sigma, St Louis, MO, USA) and the infectious media were removed the next day. For titer determination of viruses containing GFP gene, HT1080 cells were infected and GFP-positive cells were analyzed by flow cytometry 2 days after infection. Viral titer was calculated based on formula A given below.
14 To determine the titer of viruses containing TK30 gene, 143BTK
À cells were infected and selected in HAT in the presence of AZT (20 mM) starting 1 day after infection. One week after selection, the colonies were counted and titer was calculated based on formula B given below. In order to compare the titer of viruses produced at different days post-transfection, we replaced fresh medium 1 day before harvesting the viral supernatant.
A: transduction units (TU)/ml ¼ (number of cells immediately before infection Â percentage of GFP-positive cells/dilution factor B: colony forming units (CFU)/ml ¼ number of colonies after selection/dilution factor.
In vitro viral replication assay
To assess whether s-RCR vectors propagated from infected cells, the viral stock produced by 293T cells was used for the first round of infection. Supernatants were then harvested from infected cells to transduce fresh target cells (second round of infection). The third round of infection used viral supernatants harvested from target cells used in the second round of infection. Infectious supernatants were always removed 1 day after infection, cells were washed with PBS and fresh medium was added to the cells. Viral propagation (or progeny virus in the supernatant) was tested by flow cytometry for GFP or by performing TK30/GCV killing activity on infected cells. Productive infection of MFG-VSVG vector was monitored by observing syncytium formation on BHK-21 cells.
Preparation of viral producer cells for in vivo experiments
MFGgagpoliresTK30 (or MFGgagpoliresGFP) and MFG-VSVG was co-transfected into 293T cells seeded at 4 Â 10 6 cells in a 10-cm plate 1 day before transfection. Six days following transfection, 293T cells were harvested and referred to as 293T viral producer cells (293TVPCs). To prepare tumor viral producer cells (preinfected cells), 2 Â 10 5 HT1080 or 3 Â 10 5 B16 cells were seeded in sixwell plates 1 day before infection. To increase gene transfer, a centrifugation protocol 41 (321C at 1200 g for 90 min) was used during infection. We optimized the amount of virus used for infection in order to obtain cells that were both viable and producing high titer of progeny viruses, at the time when they were harvested to be used for implantation (data not shown). Viruses used to generate viral producer cells were derived from supernatants harvested between 2 and 4 days posttransfection of 293T cells. HT1080 cells were infected with approximately 20 TU/cell of virus, whereas B16 cells were infected with 40 TU/cell of virus during two rounds of infection at 8 h intervals. All preinfected cells were harvested and immediately used for in vivo injection at 2 days post-infection. Cells were washed with PBS ( Â 3) and resuspended in PBS at the concentration required for injection in a volume of 100 ml.
In vivo studies
All experimental procedures were approved by the Mayo Foundation Institutional Animal Care and Use Committee. All of our mouse studies are carried out by a veterinary technician who is blinded to the experimental groups. Tumors are measured by her and results sent to the investigators. Athymic nu/nu mice and C57BL/6 mice were age-and sex-matched for individual experiments. To establish subcutaneous tumors, 1 Â 10 6 of HT1080 cells in 100 ml PBS were inoculated s.c. into the right flank of nu/nu mice and 5 Â 10 5 of B16 cells were inoculated into C57BL/6 mice. When the tumors became palpable, animals were randomly assigned to different groups. Tumors were measured with a caliper three times weekly and the animals were killed when their tumors reached 1.0 cm in either direction. Three days following injection of HT1080 tumor cells, 3.0 Â 10 7 CFU of semi-TK30 virus, suspended in 100 ml of PBS, was injected. For treatment of B16 murine melanoma, 3.0 Â 10 7 CFU of semi-TK30 virus, 1 Â 10 6 of preinfected B16 cells (B16VPCs) or 4 Â 10 6 of 293T viral producer cells (293TVPCs) was injected 6 days following tumor cell inoculation. The injection of vectors, or viral producer cells, was given intratumorally on 3 consecutive days. Then, GCV 25 mg/kg (or PBS) was administrated i.p. twice daily for 14 days starting 2 days after the last injection. Tumor volume was determined by the formula 0.5 Â length Â width Â width.
Flow cytometry analysis of GFP expression
Cells cultured in vitro were trypsinized and pelleted for FACS analysis. Tumors removed from mice that were killed were fragmented and passed through a cell strainer, and the cells were collected and washed by PBS after lysing red blood cells. Flow analysis of GFP expression was performed immediately after the tumor tissues were dissociated. Analysis regions were set to 
PCR and Southern blot
Total DNA was extracted from cultured cells or tissues using the DNeasy Tissue Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. A 2 mg portion of DNA was amplified by PCR using primers specific for the target genes. PCR was performed in a 50 ml reaction mixture with 250 mM of each dNTP, 100 nM of primers, 5 ml of 10 Â buffer and 1 U of Taq DNA polymerase (Applied Biosystems, Foster City, CA, USA; Roche, IN, USA). The PCR was performed at 951C for 1 min, 551C for 1 min and 721C for 1 min using 30 cycles following by 721C for 10 min. The PCR product was analyzed by agarose gel electrophoresis (1%) in TAE buffer containing 0.2 mg/ml ethidium bromide. In all experiments, a mock PCR (without added DNA) was performed to exclude contamination. The vector containing GFP or VSV-G gene was detected using the following primers: Forward PRIMER (GFP) 5 0 -ATGGTGAGCAAG GGCGAGGAGC-3 0 and reverse primer (GFP) 5 0 -TACTT GTACAGCTCGTCCATGC-3 0 ; forward primer (VSV-G) 5 0 -CGAGGAATTCTCATGAAGTGCCTTTTGTACTTAG CC-3 0 and reverse primer (VSV-G) 5 0 -GGATCCTTACTT TCCAAGTCGGTTCATCTCTATGTCT-3 0 . In Southern blot analysis, 4 mg DNA was digested by NheI, loaded in a 1% agarose gel and then transferred to Nytran SuPerCharge Nylon membrane (BioScience, NH, USA). The blots were hybridized with a GFP 32 P-labeled probe or with an LTR 32 P-labeled probe (see Figure 1 ).
Statistical analysis
Survival data were analyzed by the log-rank test. 42 Other data were analyzed by Student's unpaired two-tailed t-test. Statistical significance was determined at the level of Po0.05.
